A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

In 530 patients hospitalized for acute HF, empagliflozin treatment resulted in early, clinically meaningful decongestion compared with placebo. The magnitude of decongestion was associated with clinical benefit at day 90.

AHA 2022 Paul Kalra shares the results of the IRONMAN study that investigated the effects of ferric derisomaltose on cardiovascular events in patients with iron deficiency and HF.

Three experts talk about strategies on applying guideline-directed medical therapy to patients with heart failure and iron deficiency: the who, why, and how.

In HF, the use of MRAs is often delayed despite being a crucial part of medical therapy. Prof. Ileana Piña and Prof. Patrick Rossignol discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for patients with HF.

Robert Mentz and Peter van der Meer discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.

Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Prof. Metra and Prof. Ponikowski talk about the significance of ischemic etiology and iron deficiency in the management of patients with heart failure.

Four experts discuss the value of the results from the DIAMOND trial and the body of clinical evidence for use of potassium binders in the management of hyperkalemia in patients with heart failure.

RAASi therapy is a critical component of HF management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. Prof. Kosiborod and Prof Stack discuss how to manage hyperkalemia while continuing to up-titrate RAASi therapy in patients with HFrEF & CKD.

In patients with HFrEF, the use of sacubitril/valsartan may allow a reduction in loop diuretic requirement, but how does sacubitril/valsartan affect longitudinal patterns in loop diuretic use in HFpEF patients?

AHA 2022 Prof. Mebazaa explains why patients and healthcare providers will love the STRONG-HF regimen of quick uptitration of HF therapies in hospitalized acute HF patients ready for discharge.